Menopause and the years around it, with type 1 in the room

What the body changes, what the diabetes work holds

The years around the end of the cycles ask the body to rewrite some of its own rules. The cycle becomes less regular before it stops; the night-time temperature changes; the sleep pattern often shifts; the mood and the energy run differently across the day. The foundations of the adult diabetes work are still the same six: TDD, ICR, ISF, IOB visibility, hypo recognition, hypo treatment. The diabetes math the reader has built over decades is largely the math the reader keeps. What changes is the body around the math, on a slower arc than the cycle-by-cycle one, on a more variable arc than the years before.

The reader is well placed for this chapter. The years of pattern-reading and the years of trace-watching are the strongest foundation the diabetes side of this conversation rests on. The work is to read the diabetes alongside the body’s slower rewriting; the team is in the room for both.

The named gap in the T1D evidence base

The honest framing on the T1D-specific menopause evidence base is that it is thin. Courtney 2025 (the T1D-specific Endocrine Connections synthesis) names the gap explicitly: the practical recommendations for menopause in type 1 diabetes draw heavily from the general menopause literature, with comparatively little T1D-specific evidence to anchor them. The Courtney 2025 framing is the right place for this part of the guide to sit: name the gap, draw what is supported by the published evidence, route the operational pieces to the teams that hold them.

The published evidence that does exist is consistent on the direction (Courtney 2025 in T1D; Slopien 2018 EMAS practical statement on menopause more broadly). The years before periods end (the term in the literature is “perimenopause”) show widening cycle variability: cycles can shorten or lengthen, the sensitivity arrow that was modest in the late luteal phase across the adult years can become harder to read, and the trace across the late-luteal days can vary more month to month than it did before. Post-menopause, insulin sensitivity may shift again; the direction varies across users.

Neither row in the box is a personal prescription; both are the framings the published evidence supports. The personal version of the pattern, read in the reader’s own trace, is what the team will use.

Hormone replacement and the diabetes layer

Hormone replacement therapy is a personal decision held with the menopause team or the GP, not with the diabetes team. The diabetes layer of the conversation is the question of whether the chosen regimen may shift insulin sensitivity in a direction that warrants a settings review with the diabetes team. The ADA 2026 §15 framing (women’s health) is the conservative one: hormone replacement can shift glycaemia in some users, in either direction; a settings review at the start of a new regimen and again at three months is appropriate, the same pattern as for contraception in Part 2.

The choice of whether to start hormone replacement, which regimen, for how long, and with which surveillance is the menopause team’s and the GP’s together. The diabetes team is not in the lead on that decision. What the diabetes team is in the lead on is the question of how to read the trace after any new regimen starts, and what settings change (if any) the trace warrants.

The two teams in the room

The years around the end of the cycles often bring a second team into the conversation. In some trusts the menopause team is a single clinic the GP refers into; in others the conversation lives with the GP throughout, with onward referral to a specialist menopause service only if the picture warrants it. Either pattern is the operational shape of how the menopause conversation runs; both sit alongside the diabetes conversation rather than in place of it.

The reader is the operational anchor for both conversations. The diabetes team reads the trace and holds the settings conversation; the menopause team holds the hormone-replacement and the symptom-management conversation. The two teams may communicate directly through the GP or through a shared letter; in some trusts they meet in one clinic, in others they do not. The reader brings the trace and the question to both; the teams do the work in their own lanes.

Questions to bring to the next menopause and diabetes reviews

The next reviews on both sides are the conversations that tie the menopause and the diabetes work together. The questions that move the reviews forward most reliably are the specific ones drawn from the reader’s own data and the reader’s own symptom pattern, rather than the broad ones drawn from the literature.

Bring the cycle pattern (or the absence of it) over the last three months. Bring the CGM trace across the last three months marked with any new symptom pattern (hot-flush nights, sleep-pattern changes, mood shifts). Bring the question about whether the trace pattern warrants a settings review with the diabetes team. Bring the hormone-replacement question to the menopause team or the GP if the reader is considering it; bring the diabetes layer of the hormone-replacement question to the diabetes team once a regimen is started. Bring the follow-up cadence question to both teams; the cadence often steps up in the years around the end of the cycles as the picture becomes more variable, and the team will help shape the cadence that fits the work.